Skip to main content
AVIR logo

AVIR · Atea Pharmaceuticals, Inc. · Webcasts, Transcripts & Audio

Track AVIR — free
$3.96 +0.03 (+0.76%) At close · Nov 20 Play latest call Q3 2026 earnings call transcript
Market Cap
$318.00M
Shares
80.30M
Volume · Nov 20 416.47K Avg daily vol (3M) 289.48K

Atea Pharmaceuticals, Inc. Webcasts

Earnings calls, investor updates, investor days and conferences for Atea Pharmaceuticals, Inc. (AVIR), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.

Earnings call
FY26 · Q3
2026-11-09
Atea Pharmaceuticals, Inc. (AVIR) Q3 2026 Earnings Call Transcript
Confident tone HCV Phase III clinical success HEV pipeline advancement Financial position and financing
Diluted EPS
$-0.40
Rev · 3q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-09-15
Atea Pharmaceuticals, Inc. (AVIR) September 15, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q2
2026-08-12
Atea Pharmaceuticals, Inc. (AVIR) Q2 2026 Earnings Call
Diluted EPS
$-0.41
Rev · 3q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY26 · Q1
2026-05-12
Atea Pharmaceuticals, Inc. (AVIR) Q1 2026 Earnings Call Transcript
Confident tone Phase 3 HCV pivotal trials Hepatitis E (HEV) program / AT587 U.S. launch preparation
Diluted EPS
$-0.57
Rev · 3q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-03-05
Atea Pharmaceuticals, Inc. (AVIR) Q4 2025 Earnings Call Transcript
Confident tone Commercial launch preparation Hepatitis C market opportunity Phase 3 HCV program execution
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-12
Atea Pharmaceuticals, Inc. (AVIR) Q3 2025 Earnings Call Transcript
Confident tone Hepatitis E pipeline expansion Phase III CBEYOND and C FORWARD trials Bemifovir and riluzole regimen differentiation
Diluted EPS
$-0.53
Rev · 3q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-07
Atea Pharmaceuticals, Inc. (AVIR) Q2 2025 Earnings Call Transcript
Confident tone Unmet Need and Market Opportunity HCV Phase III Program Progress Market Research / Prescriber Preference
Diluted EPS
$-0.44
Rev · 3q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-01-14
Atea Pharmaceuticals, Inc. (AVIR) Q4 2024 Earnings Call Transcript
Confident tone Phase 3 trial design and initiation HCV market opportunity and unmet need Phase 2 results and HCV cure rate
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-11-07
Atea Pharmaceuticals, Inc. (AVIR) Q3 2024 Earnings Call Transcript
Positive tone HCV Phase III readiness HCV unmet need and patient profile FDA end of Phase II meeting
Diluted EPS
$-0.37
Rev · 3q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-07
Atea Pharmaceuticals, Inc. (AVIR) Q2 2024 Earnings Call Transcript
Confident tone COVID-19 program (bemnifosbuvir / SUNRISE-3) HCV combination program (bemnifosbuvir + ruzasvir) Phase 2 HCV leading cohort results (EASL)
Diluted EPS
$-0.48
Rev · 3q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-14
Atea Pharmaceuticals, Inc. (AVIR) Q1 2024 Earnings Call Transcript
Confident tone HCV Phase II / Phase III program COVID-19 / bemnifosbuvir program EASL data presentation
Diluted EPS
$-0.75
Rev · 3q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-02-28
Atea Pharmaceuticals, Inc. (AVIR) Q4 2023 Earnings Call Transcript
Confident tone HCV Phase 2 combination COVID-19 / SUNRISE-3 Phase 3 Regulatory pathway / Phase 3 design
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-11-08
Atea Pharmaceuticals, Inc. (AVIR) Q3 2023 Earnings Call Transcript
Diluted EPS
$-0.40
Rev · 3q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-08
Atea Pharmaceuticals, Inc. (AVIR) Q2 2023 Earnings Call Transcript
Diluted EPS
$-0.34
Rev · 3q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-05-08
Atea Pharmaceuticals, Inc. (AVIR) Q1 2023 Earnings Call Transcript
Diluted EPS
$-0.43
Rev · 3q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-02-28
Atea Pharmaceuticals, Inc. (AVIR) Q4 2022 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-07
Atea Pharmaceuticals, Inc. (AVIR) Q3 2022 Earnings Call Transcript
Diluted EPS
$-0.10
Rev · 3q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-08-08
Atea Pharmaceuticals, Inc. (AVIR) Q2 2022 Earnings Call Transcript
Diluted EPS
$-0.38
▼ 2000% YoY
Rev · 3q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-05-10
Atea Pharmaceuticals, Inc. (AVIR) Q1 2022 Earnings Call Transcript
Diluted EPS
$-0.51
▼ 250% YoY
Rev · 3q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-02-28
Atea Pharmaceuticals, Inc. (AVIR) Q4 2021 Earnings Call Transcript
Revenue
$192.18M*
Rev · 3q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-11-12
Atea Pharmaceuticals, Inc. (AVIR) Q3 2021 Earnings Call Transcript
Revenue
$32.81M
Diluted EPS
$-0.34
Rev · 3q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-08-12
Atea Pharmaceuticals, Inc. (AVIR) Q2 2021 Earnings Call Transcript
Revenue
$60.39M
Diluted EPS
$0.02
Rev · 2q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2021-05-13
Atea Pharmaceuticals, Inc. (AVIR) Q1 2021 Earnings Call Transcript
Revenue
$65.98M
Diluted EPS
$0.34
Audio Transcript Slides 8-K10-Q
Showing 1–23 of 23 webcasts
Key facts CIK 1593899 CUSIP 04683R106 13F (30d) 135 filings 118 filers Visit website Investor relations